Ironwood Pharmaceuticals (NASDAQ: IRWD) develops drugs for the treatment of gastrointestinal diseases.
The company recently launched its flagship product Linzess in the U.S to treat irritable bowel syndrome (IBS). The product was developed and commercialized in collaboration with Forest Laboratories for North America. The same product is under various development stages to promote in different geographies including Europe and Asia.
IBS is a gastrointestinal disorder caused due more »
Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort. While there is no drug to cure the condition yet, Irritable Bowel Syndrome can be managed with a number of drugs available. Synergy Pharmaceuticals (NASDAQ: SGYP) is among one of the few companies that are actively involved in looking for the right treatment for this disorder. In more »
By George S. Mack of The Life Sciences Report.
For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.
Bacteria are pure survivalists, and over billions of years they have evolved to produce ever-newer chemicals to protect themselves against other bugs, and in the last 100 years they have begun to protect themselves against the antibiotics that humans have developed from those more »
Smaller cap stocks don't get as much attention from bankers, analysts, and most other investors. Generally speaking, this leaves them less-efficiently priced than their larger peers. Hedge funds take advantage of this by dedicating their research teams to work on the little guys, and consequently, they produce a significant amount of their alpha from the small-caps. According to our analysis, investing in the smart money’s top small-cap picks more »
As embarrassing and difficult to manage as chronic constipation and irritable bowel syndrome (IBS) are, there are surprisingly very few treatments available for patients at the moment. The treatments that do exist often cause diarrhea and nausea as side effects. Synergy Pharmaceuticals (NASDAQ: SGYP) has been focusing on its lead investigational drug Plecanatide, which is aimed at treating chronic constipation and constipation predominant irritable bowel syndrome.
Plecanatide is currently in more »
Ironwood Pharmaceuticals (NASDAQ: IRWD) has scored its first FDA approved drug. The official stamp was recently granted to Linzess (linaclotide), a treatment for specific types of irritable bowel syndrome and chronic constipation. The PDUFA wasn’t expected until September 8 but came in early. Investors ran up IRWD share prices to a peak of nearly $16 in the past few months while waiting for an approval, many of whom got more »
By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ
The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.